Subcutaneous Vaccination with Attenuated Salmonella enterica Serovar Choleraesuis C500 Expressing Recombinant Filamentous Hemagglutinin and Pertactin Antigens Protects Mice against Fatal Infections with both S. enterica Serovar Choleraesuis and Bordetella bronchiseptica
Open Access
- 1 May 2008
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 76 (5) , 2157-2163
Abstract
Salmonella enterica serovar Choleraesuis strain C500 is a live, attenuated vaccine that has been used in China for over 40 years to prevent piglet paratyphoid. We compared the protective efficacies of subcutaneous (s.c.) and oral vaccination of BALB/c mice with C500 expressing the recombinant filamentous hemagglutinin type I domain and pertactin region 2 domain antigen (rF1P2) of Bordetella bronchiseptica . Protective efficacy against both S. enterica serovar Choleraesuis infection in an oral fatal challenge model and B. bronchiseptica infection in a model of fatal acute pneumonia was evaluated. Both the s.c. and oral vaccines conferred complete protection against fatal infection with the virulent parent S. enterica serovar Choleraesuis strain (C78-1). All 20 mice vaccinated s.c. survived intranasal challenge with four times the 50% lethal dose of virulent B. bronchiseptica (HH0809) compared with 4 of 20 vector-treated controls and 1 of 18 phosphate-buffered saline-treated controls that survived, but no significant protection against HH0809 was observed in orally vaccinated animals. Both the s.c. and oral vaccines elicited rF1P2-specific serum immunoglobulin G (IgG) and IgA antibodies. However, lung homogenates from s.c. vaccinated animals had detectably high levels of rF1P2-specific IgG and IgA; a much lower level of rF1P2-specific IgG was detected in samples from orally vaccinated mice, and the latter showed no evidence of local IgA. Furthermore, a more abundant and longer persistence of vaccine organisms was observed in the lungs of mice immunized s.c. than in those of mice immunized orally. Our results suggest that s.c. rather than oral vaccination is more efficacious in protecting mice from fatal challenge with B. bronchiseptica .Keywords
This publication has 31 references indexed in Scilit:
- Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infectionsProceedings of the National Academy of Sciences, 2007
- Generation of monoclonal antibodies and epitope mapping of ApxIVA of Actinobacillus pleuropneumoniaeMolecular Immunology, 2006
- Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussisClinical and Experimental Immunology, 2006
- A Superoxide-HypersusceptibleSalmonella entericaSerovar Typhimurium Mutant Is Attenuated but Regains Virulence in p47phox−/−MiceInfection and Immunity, 2002
- Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium VaccineInfection and Immunity, 2002
- Identification of immunodominant epitopes in the filamentous hemagglutinin ofBordetella pertussisFEMS Immunology & Medical Microbiology, 1999
- Immunodominant Domains Present on theBordetella pertussisVaccine Component Filamentous HemagglutininThe Journal of Infectious Diseases, 1997
- Purification and characterisation of haemagglutinin from Bordetella bronchisepticaJournal of Medical Microbiology, 1993
- Characterization of haemagglutinin from Bordetella bronchisepticaVaccine, 1991
- Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussisEuropean Journal of Immunology, 1991